Friday, November 07, 2025 10:31:20 AM
I admit that i was wrong
Recent NXL News
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury • GlobeNewswire Inc. • 05/21/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 08:00:16 PM
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial • GlobeNewswire Inc. • 05/19/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 06:34:39 PM
- Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia • GlobeNewswire Inc. • 04/28/2026 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 08:30:18 PM
- Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment • GlobeNewswire Inc. • 04/22/2026 01:35:00 PM
- Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China • GlobeNewswire Inc. • 04/15/2026 02:00:00 PM
- Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents • GlobeNewswire Inc. • 04/09/2026 11:47:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 03:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 07:29:45 PM
- Nexalin launches pivotal HALO Clarity trial to support FDA submission for insomnia treatment • IH Market News • 02/24/2026 03:26:40 PM
- Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market • GlobeNewswire Inc. • 02/24/2026 01:07:00 PM
- Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders • GlobeNewswire Inc. • 02/23/2026 01:18:00 PM
- Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care • GlobeNewswire Inc. • 02/05/2026 01:37:00 PM
- Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation • GlobeNewswire Inc. • 02/02/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 10:20:32 PM
- Nexalin Technology Receives Nasdaq Listing Status Notification • GlobeNewswire Inc. • 01/23/2026 10:15:00 PM
- Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD • GlobeNewswire Inc. • 01/14/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 02:41:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 02:41:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 02:40:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 02:40:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 02:40:08 PM
